Current Affiliation Organization 【 display / non-display 】

Current Affiliation Organization 【 display / non-display 】

University 【 display / non-display 】

University 【 display / non-display 】

External Career 【 display / non-display 】

External Career 【 display / non-display 】

Affiliated academic organizations 【 display / non-display 】

Affiliated academic organizations 【 display / non-display 】

display all >>

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

display all >>

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

Acquisition of a qualification 【 display / non-display 】

Acquisition of a qualification 【 display / non-display 】

Thesis 【 display / non-display 】

Thesis 【 display / non-display 】

• Mineralocorticoid Receptor-Mediated Endothelial Function

  2008.03

Published Papers 【 display / non-display 】

Published Papers 【 display / non-display 】

• Pharmacokinetics of low doses of colchicine in the leukocytes of Japanese healthy individuals.

  Mutoh A, Uehara H, Maeda A, Tokushige A, Higashiuesato Y, Maeda M, Kumagai Y, Ueda S

  Translational and clinical pharmacology   31 ( 4 ) 217 - 225   2023.12 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

• Effects of Low-Dose Colchicine on Serum High-Sensitivity C-Reactive Protein Level in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus and Enhanced Inflammatory Response Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose-Finding Study

  Yoshikazu Miwa, Akiko Mutoh, Takeshi Morimoto, Yumi Ikehara, Takanori Yasu, Shinji Koba, Junya Ako, Yukihito Higashi, Masato Kajikawa, Hiroki Uehara, Kazuo Ishikawa, Ichiro Sakuma, Hirofumi Tomiyama, Koichi Node, Yuji Kumagai, Shinichiro Ueda

  Biomedicine Hub ( S. Karger AG )  7 ( 3 ) 156 - 164   2022.12 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Although cardiovascular mortality in Japan is lower than in other industrialized countries, clinical outcomes in coronary artery disease (CAD) patients with type 2 diabetes mellitus (T2DM) remain poor despite multiple evidence-based drug therapies and interventions. We assumed that part of residual risk in these patients may be attributable to enhanced inflammation, which can be inhibited presumably by colchicine. However, dose-responsiveness of anti-inflammatory effect of colchicine has not been elucidated. Therefore, we designed a multicenter, randomized, double-blinded, parallel-group study to explore the dose-dependent effects of low-dose colchicine on serum high-sensitivity C-reactive protein (hs-CRP) concentration and safety in CAD patients with T2DM and enhanced inflammatory response as a phase 2 study. Enhanced inflammatory response was defined as peripheral white-blood cell count ≥7,000/μL. Patients (<i>N</i> = 63) will be randomly assigned to two doses of colchicine 0.25 mg/day, 0.5 mg/day, or placebo in a 1:1:1 ratio once daily for 12 weeks. Changes in serum hs-CRP levels will be evaluated as the primary endpoint, and changes in flow-mediated vasodilation and plasma myeloperoxidase levels will be evaluated as secondary endpoints. The results of this study will contribute to the development of a protocol for a planned future phase 3 trial to estimate the reduction in CAD. The present study describes the rationale, design, and methods of the trial.

  • Access this article
    DOI
  • Search related information
    PubMed

• Effect of Short-term Colchicine Treatment on Endothelial Function in Patients with Coronary Artery Disease

  Kajikawa M, Higashi Y, Tomiyama H, Maruhashi T, Kurisu S, Kihara Y, Mutoh A, Ueda SI

  International Journal of Cardiology   281   35 - 39   2019.04 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

• Renin-angiotensin system inhibitors can prevent intravenous lipid infusion-induced myocardial microvascular dysfunction and leukocyte activation

  Takanori Yasu, Akiko Mutoh, Hiroshi Wada, Mayumi Kobayashi, Yuji Kikuchi, Shinichi Momomura, Shinichiro Ueda

  Circulation Journal ( Japanese Circulation Society )  82 ( 2 ) 494 - 501   2018 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Background: Levels of triglycerides and free fatty acids (FFAs) are elevated in patients with diabetes and may contribute to endothelial dysfunction through renin-angiotensin system (RAS) activation and oxidative stress. The present study investigated how systemic FFA loading affected myocardial microcirculation during hyperemia via RAS. Methods and Results: Eight healthy men received candesartan, perindopril, or a placebo for 2 days in a double-blind crossover design, and then myocardial microcirculation during hyperemia induced by a 2-h infusion of lipid/heparin was assessed using dipyridamole stress-myocardial contrast echocardiography (MCE). Leukocyte activity and hemorheology were also assessed ex vivo using a microchannel flow analyzer, serum levels of oxidative stress markers, and IκB-α expression in mononuclear cells. Serum FFA elevation by the infusion of lipid/heparin significantly decreased myocardial capillary blood velocity and myocardial blood flow during hyperemia. Both candesartan and perindopril significantly prevented the FFA-induced decrease in capillary blood velocity and myocardial blood flow during hyperemia. Systemic FFA loading also caused an increase in the number of adherent leukocytes and prolonged the whole blood passage time. These effects were blocked completely by candesartan and partially by perindopril. Both agents prevented the FFA-induced enhancement of oxidative stress and IκB-α degradation in mononuclear cells. Conclusions: Both candesartan and perindopril can prevent FFA-induced myocardial microcirculatory dysfunction during hyperemia via modulation of leukocyte activation and microvascular endothelial function.

  • Access this article
    DOI
  • Search related information
    PubMed

• Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

  Koichi Yabiku, Akiko Mutoh, Kazufumi Miyagi, Nobuyuki Takasu

  CLINICAL THERAPEUTICS ( ELSEVIER )  39 ( 3 ) 558 - 566   2017.03 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Purpose: Oral antidiabetic drugs (OADs) such as pioglitazone and metformin have beneficial effects in patients with nonalcoholic steatohepatitis. We prospectively assessed the effects of OADs on nonalcoholic fatty liver disease (NAFLD) in 886 men with type 2 diabetes mellitus and in a murine model of NAFLD. Methods: Patients were randomized to receive pioglitazone, metformin, sitagliptin, or a non-OAD (control) for 6 months. All the patients received dietary and exercise guidance once a month during this study. Changes in the liver-to-spleen ratio on computed tomography (CT) and NAFLD-related parameters were measured from baseline to the end of treatment. Findings: The liver/spleen ratio improved significantly in the pioglitazone and metformin groups compared with the control group (both P < 0.01), but not in the sitagliptin group (P = 0.73). The mean changes from baseline were -3.464 +/- 10.15 6%, 19.236 +/- 9.896%, 4.783 +/- 1.467%, and 1.328 0.802% in the control, pioglitazone, metformin, and sitagliptin groups, respectively. Multivariable analysis showed that the liver/spleen ratio was strongly correlated with high-sensitivity C-reactive protein concentration in the pioglitazone group (F = 9.973; P < 0.01) and abdominal visceral fat volume in the metformin group (F = 6.049; P < 0.05). Conclusions: Pioglitazone elicited the greatest improvements in features of NAFLD in type 2 diabetes mellitus. (C) 2017 Elsevier HS Journals, Inc. All rights reserved.

  • Access this article
    DOI
  • Search related information
    PubMed

display all >>

Books 【 display / non-display 】

Books 【 display / non-display 】

• Medicine and Drug Journal

  Mutoh Akiko ( Part: Multiple Authorship )

  2018.12

Other Papers 【 display / non-display 】

Other Papers 【 display / non-display 】

• Anti-atherosclerotic therapy by blocking leukocytes activity

  Akiko Mutoh-Matsushita

  Recent Advances in Clinical Pharmacology   ( 40 ) 193 - 198   2019.05

   

• Micropartieles from Endothelial Cells Serve as Circulating NO Donor

  Akiko Mutoh, Shinichiro Ueda

  CIRCULATION ( LIPPINCOTT WILLIAMS & WILKINS )  128 ( 22 )   2013.11  [Refereed]

   

• The Importance of Lipid Peroxidation in TLR4 Activation by Fatty Acids in Endothelial Cells

  Akiko Mutoh-Matsushita, Shinichiro Ueda

  CIRCULATION ( LIPPINCOTT WILLIAMS & WILKINS )  124 ( 21 )   2011.11  [Refereed]

   

• Low-dose Eplerenone Down-regulates Caveolin-1 and Improves Endothelial Function by Mechanisms Independent of MR Antagonism

  Akiko Mutoh, Mitsuhiro Nishimoto, Masashi Isshiki, Toshiro Fujita

  CIRCULATION ( LIPPINCOTT WILLIAMS & WILKINS )  118 ( 18 ) S366 - S366   2008.10  [Refereed]

   

• LOX-1 upregulation shifts endocytosis of cholera toxin from Caveolae-mediated to noncaveolae-mediated pathway in endothelial cells

  Masashi Isshiki, Akiko Mutoh, Yutaka Taketani, Yohei Takara, Tatsuya Sawamura, Kimiko Yamamoto, Joji Ando, Toshiro Fujita

  CIRCULATION ( LIPPINCOTT WILLIAMS & WILKINS )  116 ( 16 ) 295 - 295   2007.10

   

display all >>

Presentations 【 display / non-display 】

Presentations 【 display / non-display 】

• Microparticles from Endothelial Cells Serve as Circulating NO Donor

  Akiko Mutoh

  AHA Scientific Sessions  2013  -  2013 

• The Importance of Lipid Peroxidation in TLR4 Activation by Fatty Acids in Endothelial Cells

  Akiko Mutoh-Matsushita and Shinichiro Ueda

  Circulation (Supplement)  2012  -  2012 

• Blood cells’ RhoA is transcellularly delivered via microparticles to endothelial cells to get activated therein

  Akiko Mutoh

  International society of hypertension (ISH)  2012  -  2012 

• The Importance of Lipid Peroxidation in TLR4 Activation by Fatty Acids in Endothelial Cells

  Akiko Mutoh-Matsushita

  Circulation (Supplement)  2012  -  2012 

• The Importance of Lipid Peroxidation in TLR4 Activation by Fatty Acids in Endothelial Cells

  Akiko Mutoh

  AHA Scientific Sessions  2011  -  2011 

display all >>

Academic Awards 【 display / non-display 】

Academic Awards 【 display / non-display 】

• Travel Award for Young Investigators

  2013   AHA Council on ATVB  

  Winner: Matsushita-Mutoh Akiko

• IAF-J Award

  2009   The 2nd international aldosterone forum in japan  

  Winner: Matsushita-Mutoh Akiko

• Travel Grant Award

  2008   International Society of Hypertension  

  Winner: Matsushita-Mutoh Akiko

Other External funds 【 display / non-display 】

Other External funds 【 display / non-display 】

• Project Year: 2011  -  2011 

  Direct: 0 (YEN)  Overheads: 0 (YEN)  Total: 250,000 (YEN)

• Project Year: 2011  -  2011 

  Member: Akiko Mutoh-Matsushita 

  Direct: 0 (YEN)  Overheads: 0 (YEN)  Total: 150,000 (YEN)

Social Activity 【 display / non-display 】

Social Activity 【 display / non-display 】

• 2023.07

  　

  　

• 2019.07

  　

  　

• Horse manager

  2018.07

  　

  　

• 2018.05

  　

  　

  

• Horse manager

  2017.10